{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","spread":"0.00","upperLimit":"60.24","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.00","spread":"0.00","upperLimit":"52.18","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.00","spread":"0.00","upperLimit":"70.76","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"ORR was assessed for participants with AML using response criteria per European Leukemia Network Response Criteria.\n\nORR was defined as the percentage of participants who experienced either of the following based on investigator assessment:\n\n* PR\n* morphological leukemia-free state (MLFS)\n* complete remission with incomplete hematologic recovery (CRi)\n* complete remission\n* complete remission without minimal residual disease (CRmrd-).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RR AML received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG000","title":"Part 1b: 80 mg AMG 397"},{"description":"Participants with RR AML received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG001","title":"Part 1b: 160 mg AMG 397"},{"description":"Participants with RR AML received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG002","title":"Part 1b: 320 mg AMG 397"}],"paramType":"NUMBER","populationDescription":"Parts 2 and 3 were not initiated and did not enrol any participants, therefore results presented only included participants in part 1. Participants with AML were only enrolled in part 1b, so therefore data is only presented for part 1b.\n\nFAS: All participants who were enrolled and received at least 1 dose of AMG 397.","reportingStatus":"POSTED","timeFrame":"Up to end of study (a maximum of 48 weeks)","title":"Overall Response Rate (ORR) for Participants With Acute Myeloid Leukemia (AML)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}